

HEALTHCARE MONTHLY

OCTOBER 2019

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics

Medical Devices

HEADLINE TRANSACTIONS

ACQUIROR

ACQUISITION SYNOPSIS







- H. Lundbeck A/S (CPSE: LUN) entered into a definitive agreement to acquire Alder Biopharmaceuticals, Inc. (NasdaqGM: ALDR) for \$1.95 billion, a 78.9% premium
- Alder Biopharmaceuticals, Inc. develops therapeutic antibodies for the treatment of migraine headaches
- H. Lundbeck A/S develops pharmaceuticals for the treatment of psychiatric and neurological disorders





- Vertex Pharmaceuticals Inc. (NasdagGS: VRTX) entered into a definitive agreement to acquire Semma Therapeutics, Inc. for approximately
- Semma Therapeutics, Inc. develops a cell therapy for type 1 diabetes
- Vertex Pharmaceuticals Inc. develops therapies and medicines for treating cystic fibrosis and other serious diseases





- · Swedish Orphan Biovitrum (OM: SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. (Nasdaq: DOVA) for approximately \$790 million, a 36.2% premium
- Dova Pharmaceuticals, Inc. focuses on developing and commercializing drug candidates for thrombocytopenia disease
- · Biovitrum researches and develops pharmaceuticals in the therapeutic areas of hemophilia, immunology and generic & metabolic diseases

O Mobius 🔾




- · Stryker Corporation (NYSE: SYK) entered into a definitive agreement to acquire Mobius Imaging, LLC for \$370 million and up to \$130 million in milestones
- · Mobius Imaging, LLC manufactures robotics and navigation technology systems for surgical and interventional radiology procedures
- · Stryker Corporation develops orthopedics, medical & surgical equipment and neurotechnology solutions worldwide






HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*




*EBITDA Margins shown as the gray line.

LTM Stock Price Index









Target	Acquiror	Health Services Transaction
Crossix Solutions Inc.	Veeva Systems Inc.	Crossix Solutions Inc. develops a data analytics platform for media and marketing of the healthcare sector Transaction Value: \$430 million
RMDY Health, Inc.	OptimizeRx Corporation	RMDY Health operates as a provider of turnkey digital therapeutics solutions for the health and wellness industries
VitreosHealth, Inc.	HMS Holdings Corp.	VitreosHealth, Inc. provides predictive analytics and risk stratification platforms for population health management

ľ	Target	Acquiror	Life Sci / Diagnostics Transaction
	BioVectra Inc.	H.I.G. Capital, LLC	BioVectra Inc., develops bioprocessing, diagnostic, molecular biology and MPEG reagents Transaction Value: \$250 million
	Healyst Laboratory	Neuberg Diagnostics	Healyst Laboratory performs blood and urine examination for diagnostic tests
	SleepMed Incorporated	BioSerenity, SAS	SleepMed Incorporated provides sleep diagnostics and ambulatory video electroencephalography (EEG) services

Target	Acquiror	Medical Devices Transaction
Cheetah Medical, Inc.	Baxter International Inc.	Cheetah Medical, Inc. offers a NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System Transaction Value: \$190 million and up to \$40 million in milestones
Meraqi Medical Inc.	Viant Medical, LLC	Meraqi Medical Inc. develops implantable leads, neurostimulators, single-use catheters and minimally invasive surgical tools
Ophthalmic Instruments, Inc.	Advancing Eyecare Holdings	Ophthalmic Instruments, Inc. distributes ophthalmic products including aspheric/diagnostic lenses, batteries, bulbs, chin tissues/pins and contact lens supplies

Selected TM Capital Healthcare Experience







TM Capital's Healthcare Industry Contacts



James McLaren, Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman, Managing Director mgoldman@tmcapital.com 212.809.1419



Paul Smolevitz, Managing Director psmolevitz@tmcapital.com 212.809.1416

